2024/10/18 19:31:26 | |
---|---|
Price | |
10.735 EUR | |
Difference | 1.47% (0.16) |
ISIN | JP3942400007 |
Symbol | 4503 |
Exchange | Duesseldorf |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 19,402 EUR |
Benchmark | NIKKEI 225 |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 10.705 EUR |
High | 10.74 EUR |
Low | 10.705 EUR |
Close (prev. day) | 10.58 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 7 |
Last size | 0 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/09/27 | Global Equity Ratings | ||
2024/09/11 | Global Equity Ratings | ||
2024/09/05 | Global Equity Ratings | ||
2024/08/12 | Global Equity Ratings | ||
2024/07/24 | Global Equity Ratings |
2024/10/18 19:31:26 | |
---|---|
Price | |
10.735 EUR | |
Difference | 1.47% (0.16) |
ISIN | JP3942400007 |
Symbol | 4503 |
Exchange | Duesseldorf |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 19,402 EUR |
Benchmark | NIKKEI 225 |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 10.705 EUR |
High | 10.74 EUR |
Low | 10.705 EUR |
Close (prev. day) | 10.58 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 7 |
Last size | 0 |
6m | 1Y | 3Y | |
Perf (%) | +20.97% | -9.75% | -27.37% |
Perf (abs.) | +1.86 | -1.16 | -4.05 |
Beta | 0.28 | 0.29 | 0.47 |
Volatility | 26.74 | 26.45 | 25.39 |
Ø price 5 days | Ø volume 5 days (pcs.) | 10.546 EUR (0) |
Ø price 30 days | Ø volume 30 days (pcs.) | 10.713 EUR (7) |
Ø price 100 days | Ø volume 100 days (pcs.) | 10.099 EUR (2) |
Ø price 250 days | Ø volume 250 days (pcs.) | 10.124 EUR (4) |
YTD High | date | 11.410 EUR (2024/09/11) |
YTD Low | date | 8.548 EUR (2024/04/25) |
52 Weeks High | date | 12.220 EUR (2023/10/24) |
52 Weeks Low | date | 8.548 EUR (2024/04/25) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Tradegate | 2024/10/18 | 22:26 | 10.89 EUR | 0.00 | 1 |
Tokyo Stock Exchange | 2024/10/18 | 08:00 | 1,762.00 JPY | 65.37 | 4,579 |
Stuttgart | 2024/10/18 | 08:07 | 10.735 EUR | 0.00 | 3 |
Munich | 2024/10/18 | 15:17 | 10.77 EUR | 0.00 | 2 |
Frankfurt | 2024/10/18 | 09:27 | 10.55 EUR | 0.00 | 2 |
FINRA other OTC Issues | 2024/10/16 | 21:27 | 12.00 USD | 0.02 | 1 |
Duesseldorf | 2024/10/18 | 19:31 | 10.735 EUR | 0.00 | 7 |
Berlin | 2024/10/18 | 18:46 | 10.88 EUR | 0.00 | 7 |
ASTELLAS PHARMA INC. |
- - |
2-5-1 Nihonbashi-Honcho, Chuo-Ku - 103-8411 Tokyo |
Telefon: +81-3-3244-3000 |
Fax: + |
E-mail: - |
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan. |
Kenji Yasukawa | Chairman of Managing Board |
Bernie Zeiher | Member of Executive Committee |
Catherine Levitt | Member of Executive Committee |
Fumiaki Sakurai | Member of Executive Committee |
Hideki Shima | Member of Executive Committee |
Minoru Kikuoka | Member of Executive Committee |
Naoki Okamura | Member of Executive Committee |
Yoshihtsugu Shitaka | Member of Executive Committee |
Yukio Matsui | Member of Executive Committee |
Kenji Yasukawa | Chairman of Supervisory Board |
Eriko Sakurai | Member of Supervisory Board |
Haruko Shibumura | Member of Supervisory Board |
Hiroko Sakai | Member of Supervisory Board |
Hiroo Sasaki | Member of Supervisory Board |
Hiroshi Kawabe | Member of Supervisory Board |
Katsuyoshi Sugita | Member of Supervisory Board |
Mamoru Sekiyama | Member of Supervisory Board |
Mika Nakayama | Member of Supervisory Board |
Noriyuki Uematsu | Member of Supervisory Board |
Takashi Tanaka | Member of Supervisory Board |
Tatsuro Ishizuka | Member of Supervisory Board |
Tomokazu Fujisawa | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer